Independent register of U.S. FDA drug recalls · updated Oct 11, 2026
RxRecalls Get alerts

FDA Drug Recalls

14,806 recalls, newest first

Class II · Moderate risk

Lidocaine Patch

cGMP deviations: Temperature abuse

Terminated Temperature excursion Mckesson Medical-Surgical Inc. Corporate Office NDC 42858-0118-30 D-1004-2022
Class II · Moderate risk

Epi-Pen 2-Pak

cGMP deviations: Temperature abuse

Terminated Temperature excursion Mckesson Medical-Surgical Inc. Corporate Office NDC 49502-500-02 D-0993-2022
Class I · High risk

Insulin Glargine

Labeling: Missing label on the vial

Terminated Labeling / mix-up Mylan Pharmaceuticals Inc NDC 49502-393-80 D-0845-2022
Class II · Moderate risk

Rifampin for Injection

Failed Impurities/Degradation Specifications: High out of specification results obtained for related compound during stability testing.

Terminated Impurity / degradation Mylan Pharmaceuticals Inc NDC 67457-445-60 D-0774-2022
Class II · Moderate risk

Sermorelin Acetate 1 mg/mL

Lack of Assurance of Sterility: deviations from Current Good Manufacturing Practices (CGMP) that call into question the sterility of products intended to be sterile.

Terminated Sterility / contamination North American Custom Laboratories, LLC dba FarmaKeio Superior Custom Compounding D-0781-2022
Class II · Moderate risk

PT-141 (Bremelanotide Acetate)

Lack of Assurance of Sterility: deviations from Current Good Manufacturing Practices (CGMP) that call into question the sterility of products intended to be sterile.

Terminated Sterility / contamination North American Custom Laboratories, LLC dba FarmaKeio Superior Custom Compounding D-0780-2022
Class II · Moderate risk

Melanotan II 1 mg/mL

Lack of Assurance of Sterility: deviations from Current Good Manufacturing Practices (CGMP) that call into question the sterility of products intended to be sterile.

Terminated Sterility / contamination North American Custom Laboratories, LLC dba FarmaKeio Superior Custom Compounding D-0779-2022

Recalls by year